SGMT - Sagimet Biosciences Inc. News

Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of De

52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label E

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel

Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Sagimet Biosciences (NASDAQ: SGMT - Get Free Report)'s stock had its "buy" rating reaffirmed by inve

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with

Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch

Sagimet Biosciences (NASDAQ: SGMT) said its licensed partner Ascletis reported positive 52-week resu

marketbeat.com

Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch

Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week result

Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and ra

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Fund

FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and r

Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

seekingalpha.com

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifansta

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifan

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $1

Sagimet posts 52-week denifanstat acne data

What happened Sagimet Biosciences Inc. (NASDAQ: SGMT) said denifanstat produced a 57.8% treatment su

Sagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit

Underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per shar

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Sto

FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agre

Effective September 30, 2026, the Company suspended and terminated the prospectus supplement (the &#

Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Ex

In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne rece

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-L

FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and i

Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18

Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Ove

Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SG

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Biotechnology investing is a strange corner of the market. A company can own a drug that may even

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus rati

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with

Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Seve

All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollm

All clinical trial sites identified and CRO retained Patient screening expected to begin in October

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

marketbeat.com

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, o

Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in A

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to in

Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and

Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the an

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Und

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday'

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu

Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid

Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company a